Status:
UNKNOWN
Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLC
Lead Sponsor:
Guangdong Association of Clinical Trials
Conditions:
Advanced Non-squamous NSCLC
Eligibility:
All Genders
18-120 years
Phase:
PHASE4
Brief Summary
Evaluate the efficacy and safety of Anlotinib plus Pemetrexed as the 1-line treatment of patients with Platinum intolerant advanced non-squamous NSCLC, with Pemetrexed control.
Detailed Description
Anlotinib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. Anlotini...
Eligibility Criteria
Inclusion
- ≥70 years old and ECOG PS=0-2 or ≥18 years old and ECOG PS=2
- Diagnosed with advanced or recurrent non-squamous NSCLC (phase IIIB/IV) through pathology, with measurable nidus(using RECIST 1.1)
- No prior systemic treatment for non-squamous NSCLC
- Negative in EGFR\&ALK\&ROS1
- Main organs function is normal
Exclusion
- Have any habitus or medical history of hemorrhage, however severe it is; the patients who have non healing wounds, ulcer or fracture after any events with hemorrhage or bleeding
- Symptoms of brain metastases cannot be controlled and treated within less than 21 days
- Have participated in other clinical trials of anti-tumor medicine within 4 weeks
- Get any severe diseases or the ones that cannot be controlled
Key Trial Info
Start Date :
November 26 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 26 2020
Estimated Enrollment :
106 Patients enrolled
Trial Details
Trial ID
NCT03768037
Start Date
November 26 2018
End Date
November 26 2020
Last Update
December 7 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Chest Hospital
Beijing, Beijing Municipality, China, 101149